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Maternal serum zinc deficiency in 
cases of neural tube defect in Gorgan,
north Islamic Republic of Iran 
M.J. Golalipour,1 M.A.Vakili,2 A.R. Mansourian3 and E. Mobasheri1 
 ةيملاسلإا ناريإ ةيروهجم لماش في ناجرج في ،يبصعلا بوبنلأا بويع تلااح في تاهملأا لاصمأ في كنزلا زوع
يشربم مالهإ ،نايروصنم اضر دازأ ،لييكو ليع دممح ،روبيلعلك رفعج دممح
 ةيروهجم لماش في ناجرج في يبصعلا بوبنلأا بويع نم ةعفترم تلادعم  ةقباس تاسارد ترهظأ :ةـصلالخا
 نوثحابلا  نراقي  2004و  2003  يماع  في  تيرجأ  يتلا  دهاوشلاو  تلااحلل  ةساردلا  هذه  فيو  .ةيملاسلإا  ناريإ
 ،يبصعلا بوبنلأا بويعب ينباصلما نادلولا تاهمأ نم 23  ىدل ،تايرغتلما نم اهيرغو لصلما في كنزلا تايوتسم
 في كنزلا تايوتسم يطسو نأ اودجو  دقو .ناجرج في نيايزيد ىفشتسم في ءاحصأ نادلول تاهملأا نم 36  عم
 ل/لومكم  11.41  دهاوشلا  فيو )6.3  يرايعم  فارحناب(  ل/لوموركم  13.43  غلبي  ةيضرلما  تلاالحا  في  لصلما
 فوحتلا  ليلتح رهظأ دقو .)%19.4(  دهاوش 7و )%36.5(  ةلاح 13  في كنزلا زوع دجوو .)6.3  يرايعم فارحناب(
 %95  ةقث ةلصافب 5.56  ةيحجرلأا لدعم(  كنزلا زوع ينبو يمضلها بوبنلأا بويع دوجو ينب اطبارت  يتسجوللا
.)16.94و 1.51  ينب ةيحجرلأا لدعم حوارت عم
َّ
َْ
َّ
ُّ
ً
َّ
ABSTRACT Previous studies have shown a high rate of neural tube defects (NTD) in Gorgan, northern 
Islamic Republic of Iran. This case–control study during 2003–04 compared serum zinc levels and other 
variables in 23 mothers of neonates affected with NTD and 36 mothers with normal healthy neonates in 
Dezyani hospital in Gorgan. Mean serum zinc levels in the case and control groups were 13.43 µmol/L 
(SD 6.3) and 11.41 µmol/L (SD 6.3) respectively. Zinc deficiency was found in 13 (36.5%) of the cases 
and 7 (19.4%) of the controls. Logistic regression analysis showed an association between the pres­
ence of NTD and zinc deficiency (OR 5.06; 95% CI: 1.51–16.94). 
Diminution du zinc sérique chez la mère et anomalies du tube neural à Gorgan (nord de la 
République islamique d’Iran) 
RÉSUMÉ De précédentes études ont montré un taux élevé d’anomalies du tube neural (ATN) à 
Gorgan (nord de la République islamique d’Iran). Cette étude cas-témoins réalisée en 2003-2004 a 
comparé les niveaux de zinc sérique et d’autres variables chez 23 mères de nouveau-nés présentant 
des ATN et chez 36 mères ayant donné naissance à des enfants en bonne santé à l’hôpital Dezyani de 
Gorgan. Les taux  moyens de zinc sérique dans le premier et le deuxième groupe étaient respectivement 
de 13,43 µmol/L (E.T. 6,3) et de 11,41 µmol/L (E.T. 6,3). Une carence en zinc a été constatée chez 
13 mères (36,5 %) dont le nouveau-né souffrait d’ATN et chez 7 mères (19,4 %) appartenant au groupe 
témoin. L’analyse de régression logistique a montré un lien entre la présence d’ATN et la carence en 
zinc (OR 5,06 ; IC 95 % : 1,51-16,94). 
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Introduction 
Neural tube defects (NTD) are severe con­
genital malformations which occur due to 
abnormalities in neural tube formation [1]. 
They include spina bifida, anencephaly and 
encephalocele and are an important cause of 
perinatal morbidity and mortality [2]. NTD 
are the second cause of serious congeni­
tal malformations in the United States of 
America after heart malformation [3]. 
The incidence of NTD varies by geo­
graphical zone [4]. The spectrum is wide, 
ranging from 1 per 100 live births in parts 
of China to about 1 per 5000 live births 
in Scandinavian countries [4]. In many 
countries the prevalence is approximately 
1 per 1000 births. In recent years some 
studies have shown the prevalence of NTD 
ranging from 1.76 to 5.1 per 1000 in some 
parts of the Islamic Republic of Iran [5–7]. 
Furthermore, 2 previous studies reported 
the prevalence of NTD at 2.88 per 1000 and 
3.12 per 1000 in Gorgan in the north of the 
country [8,9]. 
The etiology of these anomalies is not 
completely understood and has often been 
considered multifactorial, with genetic and 
environmental as well as nutritional factors 
playing a role [10–12]. Nutritional factors 
such as folic acid and zinc deficiency are 
believed to be important in NTD [13]. Zinc 
is a trace element required by the organism 
for multiple biological functions, including 
cell division, development and differentia­
tion. Zinc is a cofactor for many enzymes 
in various metabolic pathways, for example 
in nucleic acid synthesis [13–15]. Studies 
carried out in different parts of the world 
have shown the role of zinc deficiency in 
NTD [14–18]. 
Faced with a high prevalence of NTD in 
our region [8,9], we planned this study to 
determine the role of maternal serum zinc 
deficiency in NTD in neonates. 
Methods 
Setting 
This case–control study was conducted at 
Dezyani hospital, the main referral hospital 
with a labour facility in Gorgan, the capital 
of Golestan province in the north of the 
Islamic Republic of Iran. The hospital han­
dles more than 6000 deliveries per annum, 
accounting for the majority of deliveries 
(70%) in the city. Patients are usually from 
moderate to low socioeconomic classes. 
Sample 
To estimate the zinc level in mothers of 
neonates with NTD and healthy mothers 
with a probability of 95% and power of 
80%, sample size was estimated to be ≥ 21 
for each group. The case group comprised 
all 23 mothers who gave birth to babies 
with NTD during the study period (June 
2003 to September 2004). For the control 
group, for every case we selected the subse­
quent 2 mothers who gave birth to normal, 
healthy babies. As some of the blood sam­
ples haemolysed and some control mothers 
did not agree to enter the study, the final 
sample for the control group was 36. 
Data collection 
All babies delivered in this hospital during 
the investigation period were examined 
after delivery for NTD by a gynaecolo­
gist and later the diagnosis was confirmed 
by a paediatrician. The health of neonates 
in the control group was assessed clini­
cally by a gynaecologist and paediatrician 
before these mothers entered the study. A 
questionnaire covering all relevant clinical 
and demographic factors was filled out for 
each case and control infant by the pae­
diatrician and then completed by a nurse 
during an interview with the mothers. The 
data included: birth date, sex, birth weight, 
birth height, gestational age and type of 
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NTD. Also recorded were: parents’ ages, 
mother’s parity, mother’s previous history 
of abortions, family history of congenital 
anomalies and mother’s history of exposure 
to any type of drugs during the 1st trimester 
of pregnancy (except for folate, which is 
routinely give to pregnant women). 
A peripheral blood sample was collected 
from all mothers and the serum samples 
were analysed for zinc level by spectro­
photometric methods (Randox kit, UK). 
Zinc deficiency was defined as a zinc level 
< 10.6 µmol/L [19,20]. 
Ethical consent was obtained for the 
study from the ethical committee of Gorgan 
University of Medical Sciences. The moth­
ers’ consent was obtained prior to their 
entering the study. 
Analysis 
Student t-test, chi-squared, Mann–Whitney 
and Fisher exact tests were performed for 
statistical analysis. Odds ratios (OR) and 
95% confidence interval (CI) were calcu­
lated as part of logistic regression analysis 
using SPSS, version 11.5, in a saturated 
model using forward stepwise procedures 
modelling according to the likelihood ratio. 
Results 
We studied 23 mothers with neonates af­
fected with NTD. Age range for the case 
    
 
 
  
Table 1 Demographic characteristics of mothers with neonates affected by neural tube defects 
(NTDs) and healthy controls 
Variable Cases (n = 23) Controls (n = 36) P-value 
Maternal age [mean (SD) years] 26.9 (6.1) 25.6 (5.3) 0.38a 
Paternal age [mean (SD) years] 30.1 (6.1) 29.0 (6.1) 0.33a 
Multiparity [no. (%)] 4 (17.4) 6 (16.7) 0.48b 
Previous abortion [no. (%)] 5 (13.9) 3 (13.0) 0.62b 
History of births with NTD [no. (%)] 0 (0.0) 0 (0.0) – 
History of births with other congenital 
malformations [no. (%)] 4 (11.1) 1 (4.3) 0.35b 
aStudent t-test; bChi-squared test. 
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mothers was 21–42 years and for the case 
fathers 22–42 years. The most frequent type 
of NTD was spina bifida in 14 neonates 
(61%), followed by anencephaly in 7 (30%) 
and encephalocele in 2 (9%). The control 
group was 36 healthy mothers with normal 
babies. The ages range of the mothers of the 
controls was 17–37 years and for the control 
fathers 20–0 years. 
Multiparty (4+ pregnancies) was re­
ported in 17.4% of the case mothers and 
16.7% of the control mothers. No risk ten­
dency for NTD was found to be related to 
number of pregnancies (χ2 = 0.016, P = 
0.493). A past history of infants with NTD 
was not reported by any mother in either 
group. However, mother’s history of con­
genital malformations other than NTD was 
reported by 11.1% of the cases and 4.3% of 
the controls (Table 1). 
No statistically significant differences 
were found between the groups for any of 
the demographic or family history variables 
(Table 1). 
The mean gestational age for the cases 
was 36.39 weeks [standard deviation (SD) 
2.35], range 31–38 weeks, and for controls 
38.53 weeks (SD 0.81), range 36–39 weeks 
(P = 0.001) (Table 2). 
The mean serum zinc level in moth­
ers of NTD neonates [11.41 µmol/L (SD 
6.3), range 2.2–35.4] was lower than in the 
control group [13.43 µmol/L (SD 6.3) range 
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Table 2 Birth and gestational characteristics of neonates affected by neural tube defects and 
healthy controls 
Variable Cases (n = 23) Controls (n = 36) P-value 
Birth weight [mean (SD) g] 2910 (726) 3460 (490) 0.001a 
Birth height [mean (SD) cm] 46.4 (4.75) 49.7 (2.50) 0.006a 
Gestational age [mean (SD) weeks] 36.39 (2.35) 38.53 (0.81) 0.001b 
Maternal exposure to drugs in 1st 
trimester [no. (%)] 6 (26.1) 1 (2.8) 0.011c 
Low maternal serum zinc levele [no (%)] 13 (56.5) 7 (19.4) 0.003d 
aStudent t-test; bMann–Whitney test; cFisher exact test; dchi-squared test; e< 10.6 µmol/L. 
      
  
  
   
      
     
 
 
  
    
      
      
 
 
     
  
      
      
6.2–38.2], but not statistically significantly 
so (P = 0.092). Significantly more of the 
cases (n = 13, 56.5%) than the controls had 
zinc deficiency (n = 7, 19.4%) (serum zinc 
< 10.6 µmol/L) (P = 0.003) (Table 2). 
Medications consumed during preg­
nancy in the case group were antibiotics 
and analgesics for urinary tract infections 
(4), propranolol for bicuspid valve prolapse 
(1) and anti-hyperthyroid drugs (1) (Table 
2). In the control group 1 mother had been 
exposed to antibiotics. This difference was 
significant (P = 0.007). 
Logistic regression analysis of the sig­
nificant variables showed an association 
between the presence of NTD and zinc 
deficiency (OR 5.06; 95% CI: 1.51–16.94; 
P = 0.008) and drug consumption during 
the 1st trimester (OR 13.12; 95% CI: 1.31– 
130.97; P = 0.028) (Table 3). 
Discussion 
The results of this study indicated that there 
was an association between NTD in ne­
onates and zinc deficiency in mothers. Our 
findings are similar to results from research 
in Canada [15], France [21], California 
[14] the Netherlands [22] and elsewhere 
[23–25]. Our findings are also comparable 
with studies in neighbouring Turkey. In a 
case–control study, Cengiz et al. found that 
serum zinc levels in mothers with NTD 
were significantly lower than in controls 
[26]. Cavdar et al. showed that maternal se­
rum and hair zinc concentrations in the NTD 
group were lower than those in the control 
group [16]. Other researchers, however, re­
ported no relation between zinc deficiency 
and NTD [27–30]. One study showed a sig­
nificant relation between maternal nutrition 
during pregnancy and NTD [31]. 
The diversity of functions in the or­
ganism has yielded diverse hypotheses 
to explain the association between zinc 
deficiency and NTD. Abnormal synthesis 
of nucleic acids and proteins, abnormal 
polymerization of tubulin, chromosome de­
fects, excessive cell death and an increase in 
cell membrane lipid peroxidation in humans 
may be due to zinc deficiency [32]. A prom­
ising finding for the prevention of NTD has 
been the discovery of the protective effect of 
 
  
 
 
  
  
  
Table 3 Logistic regression analysis of the 
variables included in the study 
Risk factor Adjusted 95% CI P-value 
OR 
Low maternal 
serum zinc 
level 5.06 1.51–16.94 0.008 
Maternal 
exposure 
to drugs in 
1st trimester 13.12 1.31–130.97 0.028 
OR = odds ratio; CI = confidence interval. 
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folic acid [33–37], leading to recommenda­
tions for folate supplementation in the diet 
of pregnant women. It has been noted that 
the periconceptional use of folate supple­
ments also reduced the incidence of NTD 
[38]. In a systematic review of case–control 
studies, a moderate association between low 
maternal vitamin B12 status and the risk of 
fetal NTD was noted [39]. 
Although folic acid supplementation 
programmes have been implemented for 
pregnant women in many countries, NTD 
continue to be one of the most frequent 
congenital malformations worldwide. This 
directed us to presume that not all NTDs are 
related to folic acid, and that other genetic 
and nutritional factors may play an impor­
tant role. According to the MRC Vitamin 
Study Research Group report, only 70% 
of NTDs were prevented by supplemental 
folic acid, and that zinc deficiency could 
also play a role [14,15,23,40,41]. 
Recently, Velie et al. studied the peri­
conceptional use of vitamins, minerals and 
food supplements in mothers of 430 babies 
with NTD and 429 controls. They found 
a protective effect of zinc on NTD [14]. 
Folic acid and zinc deficiencies have been 
proposed elsewhere as possible causes of 
NTD [42]. Therefore administration of zinc 
during pregnancy is at least as important as 
folic acid [43]. An American study showed 
that higher preconceptional intake of nutri­
ent zinc decreased the risk of NTD [23]. 
Other studies have also indicated a mod­
erate association between low maternal B12 
status and the risk of fetal NTD [39,44]. 
Afman et al. suggested that vitamin B12 
supplementation might therefore be war­
ranted for prevention of NTD [44]. 
Genetic factors have also been hypoth­
esized. Some researchers in the Eastern 
Mediterranean Region have reported that 
consanguinity in parents of babies with 
NTD is high [45,46]. 
The other significant difference between 
the cases and controls in the present study 
was the consumption of medications in the 
1st trimester of pregnancy, a factor that is 
widely accepted as a cause in congenital 
malformations. A study in Turkey reported 
a significant relation between medication 
during pregnancy and NTD [31]. We also 
observed a shorter gestational time in cases 
than in controls and a lower weight and 
length in cases that were probably a result 
of the congenital malformations. 
Conclusion 
In this study, the first of its kind in this 
region, we found an association between 
NTD and low zinc levels, adding to the evi­
dence about the importance of nutritional 
and maternal health factors in the etiology 
of this disease. In addition to folic acid sup­
plementation, zinc supplementation should 
be considered for the further decrease in the 
recurrence and occurrence of NTD. 
In our opinion, it would be better to 
select the study group at 12–16 weeks of 
pregnancy after the diagnosis of NTD in the 
fetus with ultrasonography because the zinc 
concentration in mothers could change dur­
ing the next 2 trimesters. Further studies in 
humans are needed to clarify the metabolic 
interrelations between folic acid and zinc to 
provide more solid support for supplemen­
tation programmes during gestation. 
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Epidemiological transition of some diseases in Oman: a situational analysis. S.S. Ganguly, M.A. Al-Shafaee, J.A. 
Al-Lawati, P.K. Dutta1 and K.K. Duttagupta. Eastern Mediterranean health journal, 2009, 15(1):209–18. 
The name of the third author in Arabic should read تياوللا دحمأ داوج , not تياوللا ليع داوج.
دلجلما ،ةيلماعلا ةحصلا ةمظنم ،طسوتلما قشرل ةيحصلا ةلجلما  ددعلا ،شرع سمالخا٢ ،٢٠٠9
